主 頁 > 新 聞 及 資 訊

新 聞 及 資 訊   European Medicines Agency’s statement on possible drug interaction between clopidogrel and proton pump inhibitors (English only)   European Medicines Agency The Agency is aware of studies suggesting that clopidogrel may be less effective in patients receiving proton pump inhibitor (PPI), and they include omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole. Some PPIs prevent the conversion of clopidogrel into its biologically active form in the body, reducing the effectiveness of clopidogrel and increasing the risk of heart attack or other conditions involving harmful clotting (e.g. strokes). The marketing authorisation holders for the clopidogrel-containing medicines will amend the product information. The relevant link for the news is: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf Situation in Hong Kong: Clopidogrel-containing products are registered in Hong Kong. The companies are being followed up with regard to the above public statement made by European Medicines Agency. Ends/Wednesday, June 3, 2009 Issued at HKT 12:30